Zobrazeno 1 - 10
of 388
pro vyhledávání: '"Dieter Naber"'
Autor:
Christoph U. Correll, Robert E. Litman, Yuriy Filts, Jordi Llaudó, Dieter Naber, Ferran Torres, Javier Martínez
Publikováno v:
npj Schizophrenia, Vol 6, Iss 1, Pp 1-9 (2020)
Abstract To evaluate the efficacy and safety of Risperidone ISM® against placebo in patients with acute exacerbation of schizophrenia. A multicenter, randomized, double-blind, placebo-controlled study was conducted between June 2017 and December 201
Externí odkaz:
https://doaj.org/article/485f9847ecae4df6ad9a103f3ac27f37
Autor:
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Anders Ettrup, Anna Eramo, Karina Hansen, Dieter Naber
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183475 (2017)
Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between work readiness and health-related quality of lif
Externí odkaz:
https://doaj.org/article/b5d30494aa3d4448b36c28ade08cdac6
Autor:
Gregor Leicht, Stefan Troschütz, Christina Andreou, Evangelos Karamatskos, Matthias Ertl, Dieter Naber, Christoph Mulert
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e83414 (2013)
BACKGROUND: The processing of reward and punishment stimuli in humans appears to involve brain oscillatory activity of several frequencies, probably each with a distinct function. The exact nature of associations of these electrophysiological measure
Externí odkaz:
https://doaj.org/article/12cd4ae614b2445a97989f52659e93de
Publikováno v:
Mental Illness, Vol 1, Iss 1, Pp e2-e2 (2009)
Neuroleptic non-compliance remains a serious challenge for the treatment of psychosis. Non-compliance is predominantly attributed to side effects, lack of illness insight, reduced well-being or poor therapeutic alliance. However, other still neglecte
Externí odkaz:
https://doaj.org/article/0ee2272fb9134a3989f68b26419eab54
Publikováno v:
Neuropsychiatric Disease and Treatment.
Robert Litman,1,2 Dieter Naber,3 Lourdes Anta,4 Javier MartÃnez,4 Yuriy Filts,5 Christoph U Correll6â 8 1CBH Health LLC, Gaithersburg, MD, USA; 2Department of Psychiatry, Georgetown University Medical School, Washington, DC, USA; 3Department
Autor:
Yuriy Filts, Robert E. Litman, Javier Martínez, Lourdes Anta, Dieter Naber, Christoph U. Correll
Publikováno v:
Schizophrenia Research. 246:258-259
Autor:
Javier Martínez, Lourdes Anta, Yuriy Filts, Christoph U. Correll, Robert E. Litman, Dieter Naber
Publikováno v:
Schizophrenia research. 239
Objective To evaluate long-term efficacy, safety and tolerability of Risperidone ISM® in patients with schizophrenia, a multicenter, open-label extension of the PRISMA-3 study was conducted. Methods Eligible placebo (unstable) and Risperidone ISM®
Autor:
Dieter Naber, Monika Bullinger
Publikováno v:
Dialogues in Clinical Neuroscience
Minor/subthreshold depression is associated with functional impairment, reduced quality of life, and the risk of developing into major depression. Therefore, it should be treated. Watchful waiting should be an option only for patients who, despite ad
Autor:
Dieter Naber, Monika Bullinger
Publikováno v:
Dialogues in Clinical Neuroscience
This manuscript summarizes the literature on mental health outcomes after cardiac arrest. Survivors of cardiac arrest show high rates of mental illness with more than 40% suffering from anxiety, 30% from depression, and 25% from posttraumatic stress
Autor:
Michael Riedel, Herbert Pfeiffer, Isabella Heuser, Max Schmauss, Rebecca Schennach, Joachim Klosterkötter, Ilja Spellmann, Markus Gastpar, Wolfgang Maier, Hans-Jürgen Möller, Stefan Klingberg, Richard Musil, Dieter Naber, Markus Jäger, Wolfgang Gaebel, Matthias R. Lemke, Florian Seemüller, Eckart Rüther, Lutz G. Schmidt, Gerd Laux, Michael Obermeier
Publikováno v:
Pharmacopsychiatry. 50:136-144
The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/w